Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CACNA2D1 | P54289 | 16/20 | 1.00 |
| ▸ | GABRA1 | P14867 | 4/20 | 0.67 |
| ▸ | GABRG2 | P18507 | 4/20 | 0.67 |
| ▸ | GABRB3 | P28472 | 4/20 | 0.67 |
| ▸ | GABRA3 | P34903 | 4/20 | 0.67 |
| ▸ | GABRA5 | P31644 | 3/20 | 0.67 |
| ▸ | GABRA2 | P47869 | 3/20 | 0.67 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5529384 | 0.90 | CACNA2D1 (0.82) | CACNA2D1 | |
| SCHEMBL5530122 | 0.90 | CACNA2D1 (1.00) | CACNA2D1GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL8292331 | 0.88 | CACNA2D1 (0.79) | CACNA2D1 | |
| SCHEMBL4824459 | 0.86 | CACNA2D1 (1.00) | CACNA2D1 | |
| SCHEMBL5532572 | 0.86 | CACNA2D1 (1.00) | CACNA2D1GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL5519077 | 0.85 | CACNA2D1 (1.00) | CACNA2D1 | |
| SCHEMBL4820104 | 0.85 | CACNA2D1 (1.00) | CACNA2D1GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL4820980 | 0.85 | CACNA2D1 (1.00) | CACNA2D1 | |
| SCHEMBL5530592 | 0.84 | CACNA2D1 (1.00) | CACNA2D1GABRA1GABRG2GABRB3GABRA3 | |
| SCHEMBL8293215 | 0.84 | CACNA2D1 (0.76) | CACNA2D1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1677799-A4 | TRIAZOLO-PYRIDAZINE COMPOUNDS AND DERIVATIVES THEREOF USEFUL IN THE TREATMENT OF NEUROPATHIC PAIN | MERCK & CO INC (US) | 2008-09-10 | — | — | EP | disclosed |
| US-20070213338-A1 | Triazolo-Pyridazine Compounds and Derivatives Thereof Useful in the Treatment of Neuropathic Pain | MERCK & CO., INC. | 2007-09-13 | — | — | US | disclosed |
| US-20070213338-A1 | Triazolo-Pyridazine Compounds and Derivatives Thereof Useful in the Treatment of Neuropathic Pain | MERCK & CO., INC. | 2007-09-13 | — | — | US | disclosed |
| US-20070213338-A1 | Triazolo-Pyridazine Compounds and Derivatives Thereof Useful in the Treatment of Neuropathic Pain | MERCK & CO., INC. | 2007-09-13 | — | — | US | disclosed |
| EP-1677799-A1 | TRIAZOLO-PYRIDAZINE COMPOUNDS AND DERIVATIVES THEREOF USEFUL IN THE TREATMENT OF NEUROPATHIC PAIN | Merck & Co., Inc. (US) | 2006-07-12 | — | — | EP | disclosed |
| WO-2005041971-A1 | TRIAZOLO-PYRIDAZINE COMPOUNDS AND DERIVATIVES THEREOF USEFUL IN THE TREATMENT OF NEUROPATHIC PAIN | MERCK & CO., INC. (US) | 2005-05-12 | — | — | WO | disclosed |
| WO-2005041971-A1 | TRIAZOLO-PYRIDAZINE COMPOUNDS AND DERIVATIVES THEREOF USEFUL IN THE TREATMENT OF NEUROPATHIC PAIN | MERCK & CO., INC. (US) | 2005-05-12 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070213338-A1 | Triazolo-Pyridazine Compounds and Derivatives Thereof Useful in the Treatment of Neuropathic Pain | PER2, CNR2, OPRD1 | CACNA2D1 13/4885GABRA1 95/4885GABRG2 280/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.